Etiome develops Biostaged Medicines, which aim to intervene in disease progression before it becomes irreversible. Their approach focuses on addressing diseases in earlier stages to prevent debilitating outcomes.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are diagnosed late, after irreversible damage has occurred, leading to ineffective treatments and patient decline. Current healthcare systems often react to symptoms rather than addressing the underlying causes of disease progression in its earliest stages.
Solution
Etiome is developing Biostaged Medicines by applying its Temporal Biodynamics™ platform to characterize and treat patients in the "silent-stage" of disease, before outward symptoms appear. The platform leverages multimodal population-level data, single-cell omics, and artificial intelligence to build detailed models of how biology shifts over the course of disease. By identifying Biostaged Markers, Etiome can pinpoint individuals most likely to benefit from stage-specific interventions. This approach enables the development of targeted medicines designed to slow, stop, or even prevent the damage caused by disease, delivered to the right patient population at the right time.
Target Audience
Etiome is focused on addressing serious and progressive conditions within metabolic, neurodegenerative, pre-cancerous, and autoimmune disease areas.
Features
- Temporal Biodynamics™ platform leverages complex clinical, cellular, and molecular data to characterize biology at scale and over time.
- Proprietary algorithms and software analyze real-world, population-level data to map individuals along a broad spectrum of health and disease substages.
- Phenotype-aware AI integrates multi-scale datasets to uncover temporal shifts in genes and proteins specific to each disease.
- Identification of Biostaged Markers, stage-specific biomarkers that indicate where a patient resides along the disease journey.
- Custom-built assays, informed by dynamic biological representations, enable validation of potentially transformative therapeutics.